Shorla Oncology (Health Care, Manufacturing) — Funding, Investors & Signals 2026

Shorla Oncology

At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers.

Founded 2018 Ireland

Ireland 38 employees Series B Total: $43.30M Health Care, Manufacturing +1

Shorla Oncology is an Irish healthcare startup that focuses on the development and commercialization of innovative oncology drugs, particularly targeting women's and pediatric cancers. Founded in 2018, the company's mission is to address the gaps in existing cancer treatments by providing accessible, affordable, and life-saving medications to patients in need. The company's dedicated team, comprising thought leaders, clinicians, scientists, and commercial strategists, leverages extensive experience in drug development and the commercialization of niche cancer treatments to bring about a significant clinical impact. Shorla Oncology's strategic approach is to target indications where current treatments are limited, in short supply, or insufficient for the target population. In its latest funding round, the company secured a $35.00M Series B investment on October 4, 2023. The investment was led by Kurma Partners, Enterprise Ireland, and Seroba Life Sciences, signaling not only financial support but also strategic partnerships. Shorla Oncology's commitment to addressing unmet medical needs in the oncology space, combined with its strong backing from reputable investors, positions the company to make a meaningful impact in the healthcare industry and underscores its potential for future growth and success.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	••••••	3		04 Oct 2023
Series A	••••••	2		03 Jun 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

••••••

04 Oct 2023

Series A

••••••

03 Jun 2020

FAQ About Shorla Oncology

At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers.

Shorla Oncology was founded in 2018.

Shorla Oncology is headquartered in Ireland.

Shorla Oncology operates in the following industries: Health Care, Manufacturing, Pharmaceutical.

Shorla Oncology has approximately 38 employees.

Shorla Oncology has completed 2 funding rounds, raising a total of $43.30M. The latest funding stage is Series B.

Top alternatives and competitors to Shorla Oncology include OnCusp Therapeutics, Probmet Therapeutics, Meyer FSMP Hong Kong, Pangea Biomed, Medelis, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Shorla Oncology and OnCusp Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Shorla Oncology

General Information

Track Shorla Oncology

Discover More

About Shorla Oncology

Funding Rounds & Investors (2)

Shorla Oncology Alternatives & Competitors

FAQ About Shorla Oncology

Don't just browse. Track.